The role of infliximab in the treatment of superficial granulomatous pyoderma of the head and neck  by Ibrahim, Omer et al.
J AM ACAD DERMATOL
NOVEMBER 2014
e222 LettersPunch biopsy showed a proliferation of thin,
irregular vascular spaces involving the entire dermis.
These spaces had a lobular arrangement superficially
and a more slit-like appearance deeper in the
dermis (Fig 1). No endothelial cell atypia was
present and HHV-8 polymerase chain reaction
was negative. The biopsy was reviewed by 4
board-certified dermatopathologists, including a
vascular expert in consultation, and the diagnosis
of BL was confirmed.
Before the patient’s diagnostic biopsy, his
transplant team suspected Kaposi sarcoma, given
the clinical appearance of the plaque. Given the
team’s clinical experience demonstrating slowed
Kaposi sarcoma disease progression in some cases,
sirolimus was empirically substituted for tacrolimus.
Even though the patient’s diagnosis was ultimately
confirmed as BL, sirolimus was continued because
the thigh plaque improved clinically. After 7.5
months, the patient’s lesion had decreased in size,
stabilized at 5 3 6 cm, lightened in color, and
flattened significantly (Fig 2).
Other reports have demonstrated the efficacy
of this drug in the treatment of lymphovascular
proliferative disorders such as Kaposiform
hemangioendothelioma and diffuse lymphangioma-
tosis.4,5 Evidence suggests that VEGF plays a role in
lymphogenesis by upregulating mTOR signaling.
Recent studies have shown that sirolimus
inhibits lymphogenesis by decreasing synthesis
and promoting degradation of VEGF receptor 3
(VEGFR-3).3 Taken together, these findings suggest
that, by targeting VEGFR-3, sirolimus may
represent an important therapeutic option for
patients with symptomatic BL and, importantly,
other lymphovascular proliferations with malignant
or life-threatening potential.
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superficial granulomatous pyoderma of the
head and neck
To the Editor: Superficial granulomatous pyoderma
(SGP) is a rare, chronic inflammatory disorder.1
Although considered a superficial, vegetative variant
of pyoderma gangrenosum (PG), SGP exhibits
important differences (Fig 1, A).1,2 Moreover, SGP
responds favorably to therapy, except in cases of
SGP involving the head and neck.1 We present a
patient with SGP on the face, neck, and trunk treated
with combined infliximab and topical tacrolimus,
and review all systemic therapies reported, to our
knowledge, in the treatment of SGP of the head and
neck.
An 83-year-old Caucasian man with extensive
history of cardiovascular disease presented for
nonhealing ulcers of more than 1 year’s duration
on the right temple, right postauricular neck, and
central chest (Fig 1, B). Each lesion evolved after a
surgical procedure as slowly growing ulcerative
plaques for whichmultiple therapies were attempted
but unsuccessful, including surgical debridement,
skin grafting, and hyperbaric oxygen. The patient
was on oral prednisone 20 mg daily upon
presentation in early November 2010 and had
failed several oral antibiotics. Prior biopsies of the
right temple and chest were read by an outside
Table I. Systemic and topical therapies reported in the management of superficial granulomatous pyoderma
of the face
Patient age Patient sex Treatment Response Source
83 M Gcort 1 TCN*
Ifxy
PR, 2-3 m
CR, 3 m
Present case
16 F Cyy CR, 4 m D’Epiro S, et al.5
37 F Gcortz PR, 1 m Persing SM, Laub D. Eplasty 2012;12:e56.
71 F Gcort 1 Ifx CR, 3 m Akhras V, et al.3
65 M Gcort 1 Cy CR, 5 m Cheung ST, et al. Acta Derm Venereol 2006;86:362-4.
85 M Gcort 1 IVIGx CR, 3 m Dobson CM, et al. J Am Acad Dermatol 2003;48:456-60.
44 F Cy** CR, 8 m Lachapelle JM, et al. Dermatology 2001;202:155-7.
29 M Gcort 1 Cy PR, 3 m Wildfeuer T, Albrecht G. Hautarzt 1999;50:217-20.
79 M Gcortyy PR, 1 m Murata J, et al. Clin Exp Dermatol 2006;31:74-6.
44 F Dapsone 1 Gcort CR, 6 m Peretz E, et al. Int J Dermatol 1999;38:703-6.
34 M Gcort 1 Cy, Ifxzz CR, 2-4 m Marzano AV, et al.4
CR, Complete response; Cy, cyclosporine; Gcort, glucocorticoids; Ifx, infliximab; IVIG, intravenous immunoglobulin; m, months; PR, partial
response; TCN, tetracycline.
*Topical clobetasol 0.05% ointment, intralesional triamcinolone, or topical tacrolimus 0.1% ointment was administered concomitantly.
yTopical tacrolimus 0.1% ointment was administered concomitantly.
zTopical mupirocin 2% ointment was administered concomitantly.
xTopical clobetasol 0.05% ointment or topical tacrolimus 0.1% ointment was administered concomitantly.
**Hydrocortisone-17-butyrate and an ointment containing 3% salicylic acid and 4% boric acid were applied concomitantly.
yyIntralesional triamcinolone was administered concomitantly.
zzGcort 1 Cy were administered separately from Ifx.
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and chronic inflammation.’’ Our dermatopathology
review of those biopsies demonstrated fragments
of cystic spaces in the dermis lined by well-
differentiated squamous epithelium and the
presence of zonation, a pathologic hallmark of
SGP, with neutrophils and necrosis surrounded by
granulomatous inflammation rimmed by plasma
cells (Fig 1, C ).
Diagnosed with SGP, the patient, starting in
November 2010, experienced partial relief with
continued oral prednisone 20 mg daily, oral
tetracycline 500 mg twice daily, and topical clobetasol
0.05% ointment (changed to tacrolimus 0.1%
ointment twice daily after 1 month) and intralesional
Kenalog (10mg/mL) to someareas.Hebeganmonthly
infliximab infusions (5mg/kg; 2 loadingdoses2weeks
apart) as a steroid-sparing agent in January 2011
(without concomitant oral antibiotic) and tapered
off prednisone by May 2011. He experienced
complete resolution of the ulcers over 3 months
(Fig 1, D). Infliximab, as well as tacrolimus, was
discontinued in September 2011 after 10 infusions.
He has remained in complete remission since.
Multiple treatments for SGP have been used:
topical and systemic corticosteroids, topical tacroli-
mus, tetracyclines, dapsone, cyclosporine, inflixi-
mab, and intravenous immunoglobulin.1 Systemic
treatments reported in themanagement of SGP of the
face, the location most difficult to treat, are
characterized in Table I; 81% of patients (9 of 11)had systemic glucocorticoids in their regimen, and
63% (7 of 11) required combination systemic therapy,
usually with cyclosporine. Only 3 patients, including
thepresent case, hadused antitumor necrosis factor
therapy3,4; our patient ultimately responded to sys-
temic infliximab combined with topical tacrolimus.
The approach of combining systemic therapy with
topical therapywas used in approximately 50%of the
cases (6 of 11). Overall, the time to complete
response using these different therapies for SGP of
the face ranged from 2 to 8 months. SGP must be
considered in the differential diagnosis of a chronic
nonhealing wound that lacks an infectious or
systemic etiology. Prompt recognition of SGP
enables early treatment and the opportunity to avoid
permanent disfigurement.5
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Fig 1. Superficial granulomatous pyoderma (SGP) of the head, neck, and chest. A, Schematic
comparing and contrasting SGP and classic pyoderma gangrenosum. Pertinent medical
problems in our patient were coronary artery disease after 5-vessel coronary artery bypass
graft, abdominal aortic aneurysm repair, carotid endarterectomy, and chronic kidney disease,
which made pulse steroids contraindicated. CAH, Chronic active hepatitis; IBD, inflammatory
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Collagenase ointment and topical timolol gel
for treating idiopathic pyoderma
gangrenosum
To the Editor:A 77-year-oldwomanwas admitted to a
university hospital for evaluation and treatment of a
painful and rapidly growing 7.5-3 9-cm ulcer on her
right medial ankle. Physical examination showed
ulceration with central granulation tissue and
surrounding violaceous rim (Fig 1, A). Biopsy
demonstrated dermal neutrophilic inflammation
with edematous undermining of the epidermis. Fite,
Grocott methenamine silver, and Brown-Brenn
stains by histochemistry were negative for infectious
mycobacteria, fungi, and routine bacteria. Pyoderma
gangrenosum (PG) was established as the diagnosis.bowel disease. B, SGP ulcerations on the head
ulceration was triggered by the following procedu
right jaw pain and difficulty chewing in October
repair the right temple defect; incision and draina
were noted for a 2-fold elevation in erythrocyte se
evidence of myeloproliferative disease, hepatitis
vasculitides. The patient never experienced gastr
bleeding and did not undergo a colonoscopy. C
features: plasma cells, histiocytes, sinus track epit
evidence of polarizable foreign material and per
were negative. D, Healed SGP with residual sc
intravenous infliximab and topical calcineurin inhPast medical history was noncontributory. Workup
was negative for underlying malignancy, inflamma-
tory bowel disease, and other autoimmune
processes. After intralesional steroid injection
(Kenalog 5 mg/mL, 1 mL total volume), the patient
was discharged with a 2-week oral prednisone taper
and a topical regimen consisting of clobetasol
ointment with topically applied crushed dapsone
under occlusive Biatain absorbent polyurethane
foam dressings. For the first month the lesion
responded well, and by day 33 the ulcer had
decreased to 6 3 6 cm. At this time, the patient was
given a second intralesional steroid injection
and was started on timolol maleate 0.5%
gel applied topically to the entire border of the ulcer
daily while continuing both topical clobetasol and
dapsone.
However, progress ceased during the second
month and on day 61 the ulcer was still 6 3 6 cm
(Fig 1, B). The patient wished to discontinue
topical dapsone due to discomfort and declined
systemic medications. We prescribed daily
topical collagenase 250 U/g ointment (Santyl) to
the entire ulcer bed, in addition to continued daily
topical timolol gel. Over the next 30 days, the wound
became more shallow and steadily decreased in size
from 36 cm2 to 10 cm2. After 36 more days of topical
collagenase and timolol gel under occlusion, the
ulcer was completely reepithelialized (Fig 1, C ).
There are currently no specific or uniformly
effective therapies for PG; most are directed at
reducing inflammation. One alternative approach
focuses on enhancing keratinocyte migration to
speed reepithelialization. Keratinocytes express
beta2-adrenergic receptors, and can also produce
beta-adrenergic receptor agonists that decrease
keratinocyte migration.1 Topical beta2-adrenergic
receptor antagonists such as timolol have shown
efficacy in treating chronic venous leg ulcers2 andother
recalcitrantwounds.3,4 Topical timolol gel is alsowidely
used in ulcerated infantile hemangiomas.5 Of note,
our patient used the timolol gel and not the solution., neck, and chest before treatment. Each
res: right temporal artery biopsy to evaluate
2009; attempted graft from the right neck to
ge of a cyst on the chest. Laboratory studies
dimentation rate, but otherwise there was no
, or antineutrophil cytoplasmic antibody
ointestinal symptoms such as pain or rectal
, Histopathology of SGP demonstrating 4
helial lining, and neutrophils. There was no
iodic acidSchiff and acid fast bacilli stains
ar formation on the head and neck after
ibitor therapy.
